Latest news with #BaxterInternationalInc
Business Wire
6 days ago
- Business
- Business Wire
BAXTER TO Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at and will be available for replay through Sunday, December 7, 2025. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately, 38,000 Baxter team members live our enduring mission: to save and sustain lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit and follow us on X, LinkedIn and Facebook.
Yahoo
6 days ago
- Business
- Yahoo
BAXTER TO Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025
DEERFIELD, Ill., May 27, 2025--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at and will be available for replay through Sunday, December 7, 2025. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately, 38,000 Baxter team members live our enduring mission: to save and sustain lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit and follow us on X, LinkedIn and Facebook. View source version on Contacts Media ContactSteve Brett, (224) 948-5353media@ Investor ContactClare Trachtman, (224) 948-3020 Sign in to access your portfolio
Yahoo
25-05-2025
- Business
- Yahoo
We Wouldn't Be Too Quick To Buy Baxter International Inc. (NYSE:BAX) Before It Goes Ex-Dividend
Baxter International Inc. (NYSE:BAX) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Thus, you can purchase Baxter International's shares before the 30th of May in order to receive the dividend, which the company will pay on the 1st of July. The company's next dividend payment will be US$0.17 per share, and in the last 12 months, the company paid a total of US$0.68 per share. Last year's total dividend payments show that Baxter International has a trailing yield of 2.3% on the current share price of US$30.12. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. So we need to check whether the dividend payments are covered, and if earnings are growing. Our free stock report includes 2 warning signs investors should be aware of before investing in Baxter International. Read for free now. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Baxter International's dividend is not well covered by earnings, as the company lost money last year. This is not a sustainable state of affairs, so it would be worth investigating if earnings are expected to recover. With the recent loss, it's important to check if the business generated enough cash to pay its dividend. If cash earnings don't cover the dividend, the company would have to pay dividends out of cash in the bank, or by borrowing money, neither of which is long-term sustainable. It paid out an unsustainably high 277% of its free cash flow as dividends over the past 12 months, which is worrying. Our definition of free cash flow excludes cash generated from asset sales, so since Baxter International is paying out such a high percentage of its cash flow, it might be worth seeing if it sold assets or had similar events that might have led to such a high dividend payment. Check out our latest analysis for Baxter International Click here to see the company's payout ratio, plus analyst estimates of its future dividends. When earnings decline, dividend companies become much harder to analyse and own safely. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. Baxter International reported a loss last year, and the general trend suggests its earnings have also been declining in recent years, making us wonder if the dividend is at risk. Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Baxter International has seen its dividend decline 11% per annum on average over the past 10 years, which is not great to see. While it's not great that earnings and dividends per share have fallen in recent years, we're encouraged by the fact that management has trimmed the dividend rather than risk over-committing the company in a risky attempt to maintain yields to shareholders. Remember, you can always get a snapshot of Baxter International's financial health, by checking our visualisation of its financial health, here. Is Baxter International an attractive dividend stock, or better left on the shelf? We're a bit uncomfortable with it paying a dividend while being loss-making, especially given that the dividend was not well covered by free cash flow. Overall it doesn't look like the most suitable dividend stock for a long-term buy and hold investor. So if you're still interested in Baxter International despite it's poor dividend qualities, you should be well informed on some of the risks facing this stock. Every company has risks, and we've spotted 2 warning signs for Baxter International you should know about. Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Wire
29-04-2025
- Business
- Business Wire
Baxter to Present at Bank of America Securities 2025 Health Care Conference
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:40 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at and will be available for replay through Sunday, November 9, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit and follow us on X, LinkedIn and Facebook.
Associated Press
10-04-2025
- Health
- Associated Press
Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery
Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is now available to order throughout Europe. 'For over a decade, Hemopatch Sealing Hemostat has offered surgeons a reliable solution for tissue sealing, dura sealing, and hemostasis,' said Steve Wallace, president, Advanced Surgery at Baxter. 'The product evolution to include room temperature storage is a result of close collaboration between surgeons and Baxter. Removing the need for refrigeration addresses the needs of our customers to have the product on hand in critical situations. We are proud to continue Baxter's legacy of innovation in sealing and hemostasis.' Hemopatch Sealing Hemostat is a ready-to-use absorbable collagen pad intended for tissue sealing, dura sealing and hemostasis, and is effective and safe to use in open surgery and minimally invasive surgery. In a registry of real-world data across Europe, the product has been shown to achieve rapid and sustainable hemostasis in many surgical specialties. 1 General Surgeon, Prof. Dr. med. Selman Uranüs said, 'More than 10 years ago, I first used Hemopatch Sealing Hemostat for experimental testing. Since then, I have been using it in my daily practice because of its unique characteristics as a sealing hemostatic patch, especially in laparoscopic surgery. In my opinion, eliminating the need for refrigeration and increasing product shelf life are crucial improvements because it enables surgeons to have the product available in the operating room when it matters most. After application, the product shows an enhanced adhesive strength supporting us surgeons to achieve better surgical outcomes.' 2 For more information on Hemopatch Sealing Hemostat with room temperature storage, visit About Hemopatch Sealing Hemostat Hemopatch Sealing Hemostat consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate). Due to its flexible structure, the application of Hemopatch Sealing Hemostat to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant. 3 About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit and follow us on X, LinkedIn and Facebook. INDICATIONS Hemopatch Sealing Hemostat is indicated as a hemostatic device and surgical sealant across various soft tissues (cardiovascular, connective tissue, parenchyma, serosa, viscera), and dura for procedures in which control of mild or moderate bleeding or leakage of other body fluids or air by conventional surgical techniques is either ineffective or impractical. Hemopatch Sealing Hemostat may be used to augment dura closure techniques to close small dural defects (≤3mm) following traumatic injury, excision, retraction or shrinkage of the dura mater. IMPORTANT RISK INFORMATION Hemopatch Sealing Hemostat is not recommended to be used in pulsatile, severe bleedings. The use of Hemopatch Sealing Hemostat is not recommended in the presence of an active infection. When used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, the brain and/or cranial nerves, care should be exercised to avoid overpacking as Hemopatch Sealing Hemostat may expand upon absorption of liquid, creating the potential for neural damage. Hemopatch Sealing Hemostat is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis and sealing. Do not compress Hemopatch Sealing Hemostat into blood vessels or use intravascularly. Rx Only. For safe and proper use please refer to full device Instructions for Use for Contraindications, Warnings, and Precautions. Forward-Looking Statements This release includes forward-looking statements concerning potential benefits associated with Hemopatch Sealing Hemostat . The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements. Hemopatch Sealing Hemostat and Baxter are registered trademarks of Baxter International Inc. 1 Lombardo C, Lopez-Ben S, Boggi U, Gutowski P, Hrbac T, Krska L, Marquez-Rivas J, Russello D, York E, Zacharias M. Hemopatch® is effective and safe to use: real-world data from a prospective European registry study. Updates Surg. 2022 Oct;74(5):1521-1531. doi: 10.1007/s13304-022-01353-y. Epub 2022 Aug 20. PMID: 35986865; PMCID: PMC9481486. 2 Prof. Dr. med. Selman Uranüs, is one of the speakers at the symposium and has signed a speaker agreement 3 IFU Hemopatch Sealing Hemostat 09/2024 CONTACT: Media Contact Peggy Dekker-Kühnen, (224) 948-5353 [email protected] Contact Clare Trachtman, (224) 948-3020 KEYWORD: AUSTRIA EUROPE UNITED STATES NORTH AMERICA ILLINOIS SOURCE: Baxter International Inc. Copyright Business Wire 2025. PUB: 04/10/2025 09:16 AM/DISC: 04/10/2025 09:16 AM
